The cost utility of solifenacin in the treatment of overactive bladder

被引：8

作者：

Hakkaart, Leona ^{[1
]}

Verboom, Paul ^{[1
]}

Phillips, Richard ^{[2
]}

Al, Maiwenn J. ^{[1
]}

机构：

[1] Erasmus MC, Inst Med Technol Assessment, NL-3000 DR Rotterdam, Netherlands

[2] Goffin Consultancy Ltd, Stelling Minnis, Canterbury, Kent, England

来源：

INTERNATIONAL UROLOGY AND NEPHROLOGY | 2009年 / 41卷 / 02期

关键词：

Urinary incontinence; Muscarinic receptor antagonist; Overactive bladder; Cost-utility analysis; Markov-model; INCONTINENCE; SYMPTOMS;

D O I：

10.1007/s11255-008-9448-2

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Overactive bladder may cause significant discomfort to patients. The standard therapy for overactive bladder includes behavioural therapy and sometimes medication. Recently, a new medication (solifenacin 5 and 10 mg) was developed for treatment of overactive bladder. The objective of this study was to assess the cost utility of solifenacin 5 and 10 mg for overactive bladder. We developed a Markov model to estimate the cost per quality adjusted life years (QALY) over a period of 12-months. Model parameters were based on randomized clinical trials for solifenacin 5 and 10 mg. Data on utility scores were taken from the literature. The incremental cost per QALY for solifenacin 5 mg and solifenacin 10 mg compared with placebo were A 17,602 pound and A 24,464 pound respectively. Sensitivity analyses showed that these results were robust to changes of relevant input data. Solifenacin 5 and 10 mg are cost-effective treatments in patients with overactive bladder.

引用

页码：293 / 298

页数：6